pCMV-Neo-Bam p53 R175H Citations (20)
Originally described in: Suppression of human colorectal carcinoma cell growth by wild-type p53.Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B Science. 1990 Aug 24. 249(4971):912-5. PubMed Journal
Articles Citing pCMV-Neo-Bam p53 R175H
| Articles |
|---|
| Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Sauer L, Gitenay D, Vo C, Baron VT. Oncogene. 2010 May 6;29(18):2628-37. doi: 10.1038/onc.2010.24. Epub 2010 Mar 1. PubMed |
| SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Van Meter M, Mao Z, Gorbunova V, Seluanov A. Cell Cycle. 2011 Sep 15;10(18):3153-8. Epub 2011 Sep 15. PubMed |
| Expression of galectin-7 is induced in breast cancer cells by mutant p53. Campion CG, Labrie M, Lavoie G, St-Pierre Y. PLoS One. 2013 Aug 14;8(8):e72468. doi: 10.1371/journal.pone.0072468. eCollection 2013. PubMed |
| Expression and functions of galectin-7 in ovarian cancer. Labrie M, Vladoiu MC, Grosset AA, Gaboury L, St-Pierre Y. Oncotarget. 2014 Sep 15;5(17):7705-21. PubMed |
| A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling. Chung JH, Larsen AR, Chen E, Bunz F. J Biol Chem. 2014 Nov 21;289(47):33020-31. doi: 10.1074/jbc.M114.597203. Epub 2014 Oct 8. PubMed |
| Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, Cho EJ, Han JW. Cell Death Dis. 2015 Nov 5;6:e1964. doi: 10.1038/cddis.2015.313. PubMed |
| ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Bado I, Nikolos F, Rajapaksa G, Gustafsson JA, Thomas C. Oncotarget. 2016 Mar 22;7(12):13599-611. doi: 10.18632/oncotarget.7300. PubMed |
| ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Morton DJ, Patel D, Joshi J, Hunt A, Knowell AE, Chaudhary J. Oncotarget. 2017 Jan 10;8(2):2536-2549. doi: 10.18632/oncotarget.13701. PubMed |
| Delta40p53 suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Nakade Y, Sato K, Itoh K, Konishi H, Hosokawa Y, Yoneda M. J Cell Sci. 2016 Dec 15. pii: jcs.190736. PubMed |
| Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. Wang HH, Wang YC, Wu DW, Hung CS, Chen CY, Lee H. Tumour Biol. 2017 Apr;39(4):1010428317694316. doi: 10.1177/1010428317694316. PubMed |
| Development of a genetic sensor that eliminates p53 deficient cells. Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F. Nat Commun. 2017 Nov 13;8(1):1463. doi: 10.1038/s41467-017-01688-w. PubMed |
| p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. Epub 2018 Aug 21. PubMed |
| Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer. Shin YJ, Kim Y, Wen X, Cho NY, Lee S, Kim WH, Kang GH. Clin Epigenetics. 2019 May 14;11(1):77. doi: 10.1186/s13148-019-0661-x. PubMed |
| p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. Aggarwal M, Saxena R, Asif N, Sinclair E, Tan J, Cruz I, Berry D, Kallakury B, Pham Q, Wang TTY, Chung FL. J Exp Clin Cancer Res. 2019 Jul 15;38(1):307. doi: 10.1186/s13046-019-1267-z. PubMed |
| Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53. Xu D, Tong X, Sun L, Li H, Jones RD, Liao J, Yang GY. Mol Carcinog. 2019 Nov;58(11):2052-2064. doi: 10.1002/mc.23097. Epub 2019 Aug 9. PubMed |
| The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X. FEBS Open Bio. 2020 Apr;10(4):535-545. doi: 10.1002/2211-5463.12806. Epub 2020 Mar 6. PubMed |
| Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. Tong X, Xu D, Mishra RK, Jones RD, Sun L, Schiltz GE, Liao J, Yang GY. J Biol Chem. 2021 Jan-Jun;296:100098. doi: 10.1074/jbc.RA120.014749. Epub 2020 Nov 21. PubMed |
| Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Palanikumar L, Karpauskaite L, Al-Sayegh M, Chehade I, Alam M, Hassan S, Maity D, Ali L, Kalmouni M, Hunashal Y, Ahmed J, Houhou T, Karapetyan S, Falls Z, Samudrala R, Pasricha R, Esposito G, Afzal AJ, Hamilton AD, Kumar S, Magzoub M. Nat Commun. 2021 Jun 25;12(1):3962. doi: 10.1038/s41467-021-23985-1. PubMed |
| Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis. Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, Sakai K, Nishio K, Ueda M, Ihara Y, Uchimura K, Ino K, Nishitsuji K. PNAS Nexus. 2022 Jul 25;1(3):pgac128. doi: 10.1093/pnasnexus/pgac128. eCollection 2022 Jul. PubMed |
| Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy. Oak S, Karajgikar O, Teni T. Biochem Biophys Res Commun. 2023 Oct 15;677:141-148. doi: 10.1016/j.bbrc.2023.08.016. Epub 2023 Aug 8. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.